Northwire Canada EditionThursday, July 16, 2026
Sign inSubscribe
Northwire
⌕
CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6% CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6%
Other

Microbix commercializes COVID-19 recombinant antigen

By The Northwire Desk — AI Analysis Jan 07, 2026 · 16:43 MBX · 0.24 Microbix Biosystems Inc
MBX · Price

Executive Summary

  • Microbix Biosystems Inc. has commercialized its first recombinant antigen product, specifically the nucleocapsid protein of the SARS-CoV-2 virus, for use in Quality Assessment Products (QAPs).
  • This launch marks the first commercial product from the company's January 2025 development program aimed at extending capabilities into synthetic antigen production.
  • The new internally manufactured recombinant antigen is now available at commercial scale and is being incorporated into PROCEEDx (research use only) and REDx-branded (in vitro diagnostics) QAPs to support clinical laboratory proficiency testing and quality management.

Key Details

  • Product: Recombinant nucleocapsid protein of the SARS-CoV-2 virus (COVID-19).
  • Application: Used in Quality Assessment Products (QAPs) for clinical laboratory proficiency testing (PT) and external quality assessment (EQA) programs.
  • Product Lines: Integrated into PROCEEDx-branded (research use only) and REDx-branded (in vitro diagnostics) QAPs.
  • Strategic Significance: First commercial product from the recombinant antigen development program announced in January 2025; complements Microbix’s existing expertise in native antigen production.
  • Operational Benefits: In-house recombinant production improves supply chain security and enables better cost control.
  • Market Context: SARS-CoV-2 antigen QAPs comprise a meaningful proportion of overall QAP sales, which totaled $5.6 million in fiscal 2025.
  • Company Financials: Microbix reported revenues of $18.6 million in its latest fiscal year (2025).

Notable Quotes

  • "Our teams have deep expertise in making antigen products that have the properties needed to measure and characterize the disease response in human populations -- the key to both diagnostic test design and EQA. Our dedicated scientists now have both established a recombinant platform and built our first such commercial product using this powerful technology. With this, we have added yet another tool for delivering on our commitment to meet the demanding technical requirements of the diagnostic industry." — Dr. Mark Luscher, Senior Vice-President of Scientific Affairs
Read the original news release →

More from Microbix Biosystems Inc

May 14, 2026 · 08:01

Microbix Revenue Plunges on China Sales Collapse; Cash Burn Concerns Mount Despite Q2 Stabilization

Earnings Apr 27, 2026 · 07:00

Microbix Product Validation Fails to Offset Revenue Decline and Cash Burn Concerns

Other Apr 15, 2026 · 07:00

Microbix Biosystems Showcases HCV Mimetic as Revenue Contracts Shrink and Cash Burn Accelerates

Other Mar 17, 2026 · 07:00

Microbix Presents Reference-Material Innovations at EUROGIN

Drill Results Mar 10, 2026 · 16:13

Microbix partner Sequel continues work on Kinlytic

Production / Operations Mar 10, 2026 · 07:00

Microbix's Clot-Buster Drug Project Advances

Production / Operations